SCHEMBL2087971

SCHEMBL2087971

COc1cccc(OC)c1OCO

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.65
L3MBTL1 Q9Y468 3/20 0.58
TSHR P16473 3/20 0.58
MAPK1 P28482 3/20 0.52
ALDH1A1 P00352 3/20 0.50
POLB P06746 1/20 0.49
LMNA P02545 5/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 2/20 0.46
TP53 P04637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GAA P10253 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096489 0.87 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL19118221 0.83 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL10661800 0.83 SMN1; SMN2 (0.73) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL1836069 0.79 CA1 (0.62) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL29375647 0.79 CA1 (0.62) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL2518861 0.79 SMN1; SMN2 (0.68) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL2087969 0.77 SMN1; SMN2 (0.65) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL3156651 0.77 SMN1; SMN2 (0.65) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL28586196 0.77 SMN1; SMN2 (0.65) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1
SCHEMBL568104 0.77 CYP1A2 (0.72) SMN1; SMN2L3MBTL1TSHRMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 SMN1; SMN2 3787/4885L3MBTL1 2575/4885TSHR 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.